Saturday, January 28, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Industry News

Soligenix Thermostable Biodefense Vaccine Technology Patent

by Global Biodefense Staff
May 27, 2013

Soligenix, Inc. last week announced that it has been granted a U.S. patent for its Thermovax vaccine thermostabilization technology entitled “Method of Preparing an Immunologically-Active Adjuvant-Bound Dried Vaccine Composition”.

The company, which is focused on developing products to treat inflammatory diseases and biodefense countermeasures, says the patent claims encompass composition of matter and methods for the ThermoVax technology, which is exclusively licensed to Soligenix by the University of Colorado. 

ThermoVax is a novel method of rendering aluminum salt (alum) adjuvanted vaccines stable at elevated temperatures. Alum is the most widely employed adjuvant technology in the vaccine industry.  For vaccines that are intended for long-term stockpiling, such as for use in biodefense or in pandemic situations, Soligenix says that the use of ThermoVax can lead to easier storage and the distribution of strategic national stockpile vaccines in emergency situations.

ThermoVax was developed specifically to overcome the problems that are encountered with freeze-drying vaccines that contain aluminum adjuvants while simultaneously engineering them to withstand extremes of temperature.

“We expect that the introduction of an effective technology for long-term stabilization of vaccines has the potential to be a major advance in the national effort to develop effective countermeasures and therapies for significant biothreats and emerging pathogens,” said Christopher J. Schaber, Soligenix President and CEO. 

Elimination of the cold chain could also further facilitate the use of vaccines in parts of the world with less reliable infrastructure.

Development of the technology was supported by a $9.4 million grant from the National Institute of Allergy and Infectious Diseases (NIAID) for the development of thermostable ricin (RiVax) and anthrax (VeloThrax) vaccines.

Proof-of-concept preclinical studies with ThermoVax indicate that it is able to produce stable vaccine formulations using adjuvants, protein immunogens, and other components that ordinarily would not withstand long temperature variations exceeding customary refrigerated storage conditions. These studies were conducted with the company’s aluminum-adjuvanted ricin toxin vaccine, RiVax, made under precise lyophilization conditions using excipients that aid in maintaining native protein structure of the ricin A chain, the immunogenic compound of the vaccine. 

When kept at 40 degrees Celsius for six months, all of the animals vaccinated with the lyophilized RiVax vaccine developed potent and high titer neutralizing antibodies. Confirmatory results have extended the stability to six months when the vaccine is kept at 40 degrees Celsius. 

Tags: AnthraxRicinStrategic National StockpileThermostabilityVaccines

Related Posts

DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
NISTCHO: New Living Reference Material for Producing Monoclonal Antibodies
Medical Countermeasures

NISTCHO: New Living Reference Material for Producing Monoclonal Antibodies

January 12, 2023
Load More

Latest News

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023
Biodefense Headlines – 17 January 2023

Biodefense Headlines – 17 January 2023

January 17, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC